The buyback initiative will be financed through the recent sale of a 6% stake in Gland Pharma, which generated approximately US$294 million. Despite trimming its holding, Fosun Pharma maintains a 45.76% controlling interest, ensuring the subsidiary remains a pillar of its international growth strategy. The remaining proceeds from the divestment are earmarked for debt reduction and ongoing research and development.

This capital maneuver comes as the company reports steady growth for the first half of 2026. Revenue climbed 4.75% to RMB 20,442 million, while core net profit surged 19.09% to RMB 1,144 million. By establishing this normalized repurchase mechanism, the company intends to pivot toward more consistent shareholder returns while continuing to prioritize its pharmaceutical pipeline and global market expansion.